Article Text

Download PDFPDF

AB0582 Soluble triggering receptor expressed on myeloid cells-1 (STREM-1) and adrenomedulin are elevated in patients with systemic lupus erythematosus
  1. I. Jeremic1,
  2. N. Stojanovic1,
  3. Z. Stanojevic2,
  4. B. Jovanovic3,
  5. J. Tosic2,
  6. S. Vidicevic2,
  7. A. Isakovic2
  1. 1Institute of Rheumatology, Belgrade
  2. 2Institute of Biochemistry, Belgrade
  3. 3Clinical Centre of Serbia, Belgrade, Serbia


Background Adrenomedulin is a peptide firstly isolated from human phaeochromocytoma with vasodilatory effects. Secretion of adrenomedulin is modified by inflammatory cytokines and it may be important as a suppressor of lupus nephritis activity. Triggering receptor expressed on myeloid cells-1 (TREM) is a member of immunoglobulin superfamily clearly elevated in inflammatory conditions. Some subgroups of patients with systemic lupus erythematosus-SLE may have especially elevated levels of s-TREM.

Objectives The aim of this study was to examine adrenomedulin and s-TREM levels in patients with SLE and healthy controls and to assess their relation with SLE disease activity index-SLEDAI

Methods Serum samples from 50 SEL patients and 40 healthy blood donors were analysed. Serum levels of adrenomedulin, s-TREM, complement components C3 and C3, and anti-dsDNA antibodies were measured

Results Patients with SLE had higher adrenomedulin (9.8±4.5 vs. 15.3±7.2 pg/mL, p<0.05) and s-TREM (11.7±4.1 vs. 20.3±13.1 pg/mL) (p<0.05) levels. s-TREM showed correlation with anti-dsDNA antibodies (ρ=0.405, p<0.05) and SLEDAI score (ρ=0.386, p<0.001). In multivariate analysis s-TREM did not appear as an independent predictor of SLEDAI score, while only anti-dsDNA antibodies were significant in multivariate analysis.

Conclusions Increased adrenomedulin and s-TREM are found in lupus sera. Despite of correlation with SLEDAI score, s-TREM is not better then anti-dsDNA antibodies as a predictor of SLE disease activity.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.